Last reviewed · How we verify

Treatment 5

EyeGene Inc. · FDA-approved active Small molecule ✓ Verified May 2026

Treatment 5 is a Small molecule drug developed by EyeGene Inc.. It is currently FDA-approved. Also known as: Comparator.

Treatment 5 works by

ETC-1002 is a small molecule intervention being studied in clinical trials for various conditions, including hypercholesterolemia. It is being tested in combination with atorvastatin, a commonly used cholesterol-lowering medication, in a placebo-controlled study.

At a glance

Generic nameTreatment 5
Also known asComparator
SponsorEyeGene Inc.
ModalitySmall molecule
PhaseFDA-approved

Mechanism of action

Treatment 5 is a treatment that targets

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Treatment 5

What is Treatment 5?

Treatment 5 is a Small molecule drug developed by EyeGene Inc..

How does Treatment 5 work?

Treatment 5 works by

Who makes Treatment 5?

Treatment 5 is developed and marketed by EyeGene Inc. (see full EyeGene Inc. pipeline at /company/eyegene-inc).

Is Treatment 5 also known as anything else?

Treatment 5 is also known as Comparator.

What development phase is Treatment 5 in?

Treatment 5 is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing